Skip to main content
. 2023 Feb 27;120(10):e2217199120. doi: 10.1073/pnas.2217199120

Fig. 4.

Fig. 4.

Fibrosis decreased in human lung tissues after treatment with blocking antibodies against CD47 and IL-6 in a humanized mouse model of COVID lung fibrosis. (A) Evaluation of therapeutic effects of CD47 and IL-6 inhibition on humanized mice grafted with human lung organoids infected with SARS-CoV-2 and treated with IgG or anti-IL-6/anti-CD47 blocking antibodies. (B) Representative immunofluorescence images of humanized COVID mouse treated with or without anti-CD47/anti-IL-6 antibodies highlighting the change of human immune cell infiltrates and extracellular matrix deposition. (Scale bar, 100 µm.). (C) Quantification of CD47 and collagen I expression in humanized mouse infected with SARS-CoV-2 without and with anti-CD47/anti-IL-6 treatment. (D) Representative images of histopathology demonstrating normalization of the lung structure in humanized COVID mouse model after anti-CD47/anti-IL-6 treatment. (Scale bar, 100 µm.). (E) Measurement of hydroxyproline content decreased with anti-CD47/anti-IL-6 treatment. (Scale bar, 100 µm.) Data are shown as mean ± SD of five different human lung tissue pieces per each group. Data were analyzed by the two-tailed unpaired t test; P values were labeled.